Vcare PharmaTech's Next-Generation TRK Inhibitor Eratrectinib Wins NMPA Approval for NTRK Fusion-Positive Solid Tumors
Key Insights
Eratrectinib, a next-generation TRK (search) inhibitor from Vcare PharmaTech (search), received NMPA marketing approval on June 4, 2026, for advanced NTRK fusion-positive solid tumors (search) in adults and adolescents.
Pivotal trial results showed an overall response rate of 68.5%, disease control rate of 85.2%, and median overall survival of 40.7 months, with the ORR rising to 89.7% in patients followed beyond six months.
In patients with baseline brain metastases, the ORR reached 87.5%, and for those previously treated with TRK (search)-TKIs, the ORR was 47.4%, demonstrating potent intracranial activity and efficacy in resistant populations.
On June 4, 2026, China's National Medical Products Administration (NMPA) announced the marketing approval of Eratrectinib (VC004), a next-generation tropomyosin receptor kinase (TRK (search)) inhibitor independently developed by Jiangsu Vcare PharmaTech (search) Co., Ltd. The drug is indicated for adult and adolescent patients with advanced solid tumors harboring NTRK (search) gene fusions, marking a significant milestone for domestically developed tumor-agnostic targeted therapy in China.
NTRK (search) gene fusions have been identified as oncogenic drivers across a broad spectrum of adult and pediatric solid tumors. To date, more than 229 fusion partner genes have been discovered, giving rise to 358 unique fusion-tumor pairings. Patients harboring such fusions generally face a poor prognosis: for advanced solid tumor patients who do not receive targeted therapy, median overall survival ranges from 10.2 to 12.7 months, and these patients are at elevated risk of brain metastasis. The loss of the extracellular domain in NTRK fusions renders antibody-based therapies ineffective, leaving small-molecule TRK (search) inhibitors that target the kinase domain as the primary treatment modality.
Epidemiology and Unmet Need
NTRK (search) fusions are characterized by rare mutations with a broad tumor spectrum distribution. The incidence reaches up to 90% in rare malignancies such as secretory breast carcinoma and infantile fibrosarcoma, and ranges from 5% to 25% in papillary thyroid carcinoma and Spitzoid melanoma. Real-world data from approximately 295,000 solid tumor patients worldwide indicate that NTRK fusion-positive cases account for a larger absolute number of patients among common cancer types. Collectively, patients with non-small cell lung cancer, breast cancer, soft tissue sarcoma, and colorectal cancer make up nearly 50% of all affected cases. In East Asian populations, the prevalence is higher, with an overall incidence of approximately 0.4% among Chinese patients. An estimated 15,000 new cases of NTRK fusion-positive solid tumors (search) are diagnosed in China each year.
Pivotal Clinical Efficacy
In pivotal registration clinical trials, Eratrectinib demonstrated compelling efficacy as a pan-tumor anticancer agent. The registration study results showed an overall response rate (ORR) of 68.5% and a disease control rate (DCR) of 85.2%. Among patients followed up for more than six months, the ORR reached 89.7% and the DCR was 100%, with a median overall survival (mOS) of 40.7 months.
Long-term clinical benefit metrics further underscored the durability of response. The 2-year progression-free survival (PFS) rate stood at 75.7%, and the 2-year duration of response (DOR) rate reached 85.5%, demonstrating that Eratrectinib can deliver sustained disease control and long-term remission.
Intracranial Activity and Post-TKI Efficacy
Eratrectinib showed robust efficacy in clinically challenging subgroups. For patients with baseline brain metastases, the ORR was as high as 87.5%, reflecting potent central nervous system penetration. For patients previously treated with TRK (search) tyrosine kinase inhibitors (TRK-TKIs), the ORR reached 47.4%, indicating meaningful clinical benefit even in the resistant setting.
Differentiated Molecular Design
Unlike the linear structure of first-generation TRK (search) inhibitors, Eratrectinib features a cyclic molecular structure. This structural optimization reduces off-target risks and effectively prevents the emergence of drug-resistant mutations, endowing the agent with the anti-resistance mechanisms characteristic of second-generation TRK inhibitors. The drug delivers durable and deep tumor remission with a favorable overall safety profile.
About Vcare PharmaTech (search)
Founded in 2010 by professors from China Pharmaceutical University and overseas returnee experts, Jiangsu Vcare PharmaTech (search) is a commercial-stage innovative biopharmaceutical enterprise that leverages artificial intelligence for differentiated de novo drug design. The company has been accredited as a National Key Specialized, Refined, Differential and Innovative "Little Giant" Enterprise. Headquartered in the Biotech and Pharmaceutical Valley of Nanjing Jiangbei New Area, Vcare PharmaTech operates an intelligent R&D headquarters spanning 21,000 square meters and employs over 900 staff, with technical professionals accounting for more than 84% of the workforce, including over 200 master's and doctoral degree holders.
Beyond Eratrectinib, the company's pipeline includes Sumecigrel Capsule, a novel oral P2Y12 receptor antagonist in pivotal confirmatory clinical trials for cardiovascular and cerebrovascular indications, and VC005, a next-generation highly selective JAK1 inhibitor in Phase III trials for atopic dermatitis, with additional development underway for ankylosing spondylitis, vitiligo, and alopecia areata. Over the past five years, the company has secured aggregate financing exceeding RMB 1.2 billion.